CNTX
Context Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$237.97M
P/E Ratio
—
EPS
$-0.37
Beta
1.83
52W High
$3.62
52W Low
$0.49
50-Day MA
$2.57
200-Day MA
$1.41
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Context Therapeutics Inc
Centrexion Therapeutics Corporation, a late-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel, non-opioid, and non-addictive therapies to address the unmet medical need for the treatment of chronic pain. The company is headquartered in Boston, Massachusetts.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-39.69M |
| Operating Margin | 0.00% |
| Return on Equity | -46.40% |
| Return on Assets | -29.80% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $0.66 |
| Price-to-Book | 4.03 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | 1.60 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $91.88M |
| Float | $42.72M |
| % Insiders | 1.18% |
| % Institutions | 76.80% |
Historical Volatility
HV 10-Day
105.27%
HV 20-Day
101.44%
HV 30-Day
99.65%
HV 60-Day
95.12%
HV Rank
77.8%
Volatility is currently expanding
Analyst Ratings
Consensus ($6.00 target)
3
Strong Buy7
BuyData last updated: 4/10/2026